Other News To Note
Wednesday, January 4, 2012
Astex Pharmaceuticals Inc., of Dublin, Calif., said the FDA's Oncologic Drugs Advisory Committee will discuss its supplemental new drug application for Dacogen (decitabine) for Injection at its Feb. 9, 2012, meeting. The proposed indication for the application is elderly acute myelogenous leukemia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.